We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+35.53%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$1.48B
AUM Growth
+$248M
Cap. Flow
-$58.8M
Cap. Flow %
-3.97%
Top 10 Hldgs %
45.09%
Holding
80
New
10
Increased
13
Reduced
36
Closed
16

Top Buys

Rank Stock Value
1
IFRX icon
InflaRx
IFRX
+$41.5M
2
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$30.2M
3
CCXI
ChemoCentryx, Inc.
CCXI
+$28.9M
4
CRSP icon
CRISPR Therapeutics
CRSP
+$27.7M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$27M

Top Sells

Rank Stock Value
1
TSRO
TESARO, Inc.
TSRO
+$66.8M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$46M
3
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$37.2M
4
TBPH icon
Theravance Biopharma
TBPH
+$22.6M
5
ARGX icon
argenx
ARGX
+$20.6M

Sector Composition

Rank Sector Weight
1 Healthcare 91.96%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ATRA icon
26
Atara Biotherapeutics
ATRA
$79M
$21.9M 1.48%
+22,000
New +$20.4M
SAGE
27
DELISTED
Sage Therapeutics
SAGE
$20.7M 1.4%
130,000
-53,732
-29% -$7.78M
YMAB
28
DELISTED
Y-mAbs Therapeutics
YMAB
$18.8M 1.27%
715,482
+520,714
+267% +$11.4M
CNST
29
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$17.2M 1.16%
1,271,687
– –
NKTR icon
30
Nektar Therapeutics
NKTR
$2.46B
$16.8M 1.14%
33,333
-3,134
-9% -$1.86M
TWST icon
31
Twist Bioscience
TWST
$6.19B
$16.4M 1.11%
706,064
– –
MYOV
32
DELISTED
Myovant Sciences Ltd.
MYOV
$15.5M 1.05%
+650,000
New +$13.3M
INSP icon
33
Inspire Medical Systems
INSP
$1.85B
$14.2M 0.96%
250,000
-40,239
-14% -$2.17M
GOSS icon
34
Gossamer Bio
GOSS
$88.7M
$14.2M 0.96%
+653,129
New +$13.6M
DTIL icon
35
Precision BioSciences
DTIL
$188M
$14M 0.95%
+26,001
New +$13.8M
AMRN
36
Amarin Corp
AMRN
$302M
$12.5M 0.84%
30,000
-5,000
-14% -$1.8M
ARRY
37
DELISTED
Array Biopharma Inc
ARRY
$12.2M 0.82%
500,000
-80,756
-14% -$1.68M
EIDX
38
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$11.9M 0.8%
507,564
+121,718
+32% +$1.95M
RUBY
39
DELISTED
Rubius Therapeutics, Inc
RUBY
$11.8M 0.8%
650,000
+289,090
+80% +$4.44M
ORTX
40
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$11.6M 0.79%
65,014
+27,514
+73% +$4.14M
ARNA
41
DELISTED
Arena Pharmaceuticals Inc
ARNA
$11.2M 0.76%
250,000
-50,000
-17% -$2.29M
ZLAB icon
42
Zai Lab
ZLAB
$2.09B
$10.3M 0.7%
350,000
-437,426
-56% -$12M
RARX
43
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$8.96M 0.61%
400,000
-41,000
-9% -$881K
GNFT
44
DELISTED
Genfit
GNFT
$8.4M 0.57%
+350,000
New +$8.08M
PHAS
45
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$7.99M 0.54%
839,642
-258,284
-24% -$1.02M
NBIX icon
46
Neurocrine Biosciences
NBIX
$16.9B
$7.93M 0.54%
90,000
-128,222
-59% -$10.7M
TECX
47
Tectonic Therapeutic
TECX
$550M
$6.62M 0.45%
25,000
-88,149
-78% -$16.1M
HARP
48
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$6.38M 0.43%
+67,389
New +$8.86M
KNSA icon
49
Kiniksa Pharmaceuticals
KNSA
$5.93B
$4.88M 0.33%
270,000
-561,000
-68% -$10.8M
NERV icon
50
Minerva Neurosciences
NERV
$188M
$4.78M 0.32%
75,988
– –
1
2
3 4

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return

Cormorant Asset Management's Q1 2019 Portfolio in Review

As of Q1 2019, Cormorant Asset Management held 80 positions worth $1.48B, up 20% from $1.23B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Cormorant Asset Management withdrew a net $58.8M in Q1 2019, closing 16 positions and reducing 36 holdings. Its most notable exit was TESARO, Inc., an estimated $66.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 86% a quarter earlier.

Against the trend, Cormorant Asset Management opened a new position in Lakefront Biotherapeutics American Depositary Shares worth $35M.

  • Cormorant Asset Management's largest Q1 2019 buy was Lakefront Biotherapeutics American Depositary Shares: 300,000 shares worth $35M.
  • Cormorant Asset Management added most to InflaRx in Q1 2019, an estimated $41.5M increase.
  • Cormorant Asset Management's biggest Q1 2019 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $46M.
  • Cormorant Asset Management fully exited TESARO, Inc. in Q1 2019, selling an estimated $66.8M.
  • Cormorant Asset Management's ten largest holdings make up 45% of its $1.48B portfolio in Q1 2019.
  • Cormorant Asset Management opened 10 new positions and closed 16 in Q1 2019.
  • Cormorant Asset Management's portfolio value rose 20% quarter-over-quarter to $1.48B.

Based on Cormorant Asset Management's 13F filing for Q1 2019, filed 15 May 2019.